Basal ganglia questions on Step 1 often feel like someone hid the answer inside three inhibitory neurons… and then asked you to predict movement. The good news: if you can track who inhibits whom (and what dopamine does), you can crush anything from Parkinson disease pharmacology to hemiballismus and Huntington. This post will make the direct vs indirect pathways feel automatic—then tie them to the classic presentations, imaging, and treatments you’ll see on exams.
Big Picture: What the Basal Ganglia Actually Do
The basal ganglia are not “motor cortex.” They’re a movement selection and scaling system—they help initiate desired movements and suppress competing ones.
Core outputs:
- Facilitate intended movement (direct pathway)
- Suppress unwanted movement (indirect pathway)
High-yield rule:
The basal ganglia influence movement via the thalamus, which excites motor cortex.
Key Anatomy (Know These Cold)
Major nuclei you’ll see in questions
| Structure | High-yield role | Notes |
|---|---|---|
| Striatum (caudate + putamen) | Main input from cortex | Uses GABA to inhibit downstream targets |
| Globus pallidus interna (GPi) | Main output nucleus | Tonic GABA inhibition of thalamus |
| Globus pallidus externa (GPe) | Relay in indirect pathway | Inhibits STN |
| Subthalamic nucleus (STN) | Excites GPi | Uses glutamate |
| Substantia nigra pars compacta (SNc) | Dopamine to striatum | D1 vs D2 effects are the entire game |
| Substantia nigra pars reticulata (SNr) | Output nucleus (esp eye movements) | Functionally similar to GPi |
Neurotransmitters to memorize:
- GABA: striatum, GPi/GPe outputs (inhibitory)
- Glutamate: cortex → striatum; STN → GPi; thalamus → cortex (excitatory)
- Dopamine (SNc → striatum): D1 stimulates direct, D2 inhibits indirect
- ACh (striatal interneurons): generally opposes dopamine (pro-indirect, anti-direct effect)
First Aid cross-reference (typical placement):
- First Aid (Step 1): Neuro—Basal ganglia, Parkinson disease, Huntington disease, Hemiballismus, Antipsychotics/EPS, Levodopa & dopamine agonists, Wilson disease
The “Default Setting” Concept (How to Think Like the Test Writer)
Baseline physiology
- GPi tonically inhibits the thalamus with GABA.
- That means the thalamus is being “held down” unless you actively release it.
So:
- Direct pathway = releases the thalamus → ↑ movement
- Indirect pathway = tightens the brake → ↓ movement
Direct Pathway (Go Pathway): Facilitates Movement
Wiring (step-by-step)
- Cortex excites striatum (glutamate)
- Striatum inhibits GPi/SNr (GABA)
- GPi/SNr normally inhibit thalamus; inhibiting GPi/SNr disinhibits thalamus
- Thalamus excites motor cortex → movement increases
Net effect: ↑ movement via thalamic disinhibition
Dopamine’s effect on direct pathway
- Dopamine from SNc activates D1 receptors on striatal neurons
- D1 is excitatory → strengthens the direct pathway → ↑ movement
Indirect Pathway (No-Go Pathway): Suppresses Movement
Wiring (step-by-step)
- Cortex excites striatum
- Striatum inhibits GPe
- GPe normally inhibits STN; inhibiting GPe disinhibits STN
- STN excites GPi/SNr (glutamate)
- GPi/SNr increases inhibition of thalamus
- Thalamus sends less excitation to cortex → movement decreases
Net effect: ↓ movement by increasing thalamic inhibition
Dopamine’s effect on indirect pathway
- Dopamine activates D2 receptors on striatal neurons
- D2 is inhibitory → weakens the indirect pathway → less braking → ↑ movement
One-line dopamine summary (HY):
Dopamine increases movement by stimulating D1 (direct) and inhibiting D2 (indirect).
Quick High-Yield Table: Direct vs Indirect
| Feature | Direct pathway | Indirect pathway |
|---|---|---|
| Goal | Promote movement | Suppress movement |
| Key idea | Disinhibit thalamus | Inhibit thalamus more |
| Striatum inhibits… | GPi/SNr | GPe |
| STN activity | Not essential | Increased (via disinhibited STN) |
| Dopamine effect | D1 stimulates → ↑ movement | D2 inhibits pathway → ↑ movement |
| What happens if pathway is underactive? | Hypokinesia | Hyperkinesia |
Pathophysiology + Classic Clinical Syndromes (Where This Pays Off)
Parkinson Disease (Too Little Movement)
What’s happening?
- Degeneration of SNc dopaminergic neurons → ↓ dopamine in striatum
- Consequences:
- ↓ D1 stimulation → weaker direct pathway
- ↓ D2 inhibition → stronger indirect pathway
- Net: too much GPi inhibition of thalamus → ↓ thalamocortical drive → bradykinesia
Clinical presentation (HY)
- TRAP:
- Tremor at rest (“pill-rolling”)
- Rigidity (lead-pipe/cogwheel)
- Akinesia/bradykinesia
- Postural instability
- Also: shuffling gait, masked facies, micrographia, hypophonia
Diagnosis
- Primarily clinical
- Imaging used to rule out mimics; DaTscan sometimes used but not core Step 1 logic
Treatment (Step 1/2 favorites)
- Carbidopa/Levodopa (most effective for symptoms)
- Levodopa is dopamine precursor; carbidopa inhibits peripheral dopa decarboxylase
- AEs: nausea, orthostasis, hallucinations, dyskinesias, on-off fluctuations
- Dopamine agonists: pramipexole, ropinirole
- AEs: sleep attacks, impulse control disorders, hallucinations
- MAO-B inhibitors: selegiline, rasagiline
- COMT inhibitors: entacapone (peripheral), tolcapone (central + peripheral; hepatotoxicity)
- Amantadine (↑ dopamine release; also NMDA antagonist) — helps dyskinesias
- Antimuscarinics (benztropine, trihexyphenidyl) — best for tremor
First Aid cross-reference: Parkinson drugs + EPS are major FA pharm tables.
Huntington Disease (Too Much Movement + Psychiatric/Cognitive)
What’s happening?
- AD CAG repeat expansion (anticipation)
- Degeneration of striatum, especially neurons of the indirect pathway
- Net: less indirect braking → thalamus more active → hyperkinesia (chorea)
Clinical presentation
- Chorea (“dance-like” movements)
- Psychiatric changes (depression, irritability)
- Cognitive decline → dementia
- Weight loss is common
Diagnosis
- Genetic testing (CAG repeats)
- Imaging may show caudate atrophy and enlarged lateral ventricles (classically)
Treatment (symptomatic)
- VMAT inhibitors: tetrabenazine, deutetrabenazine (reduce DA release)
- Antipsychotics can help chorea/behavior (but can cause parkinsonism)
High-yield association:
Huntington = loss of indirect pathway → hyperkinesia.
Hemiballismus (Wild Flailing)
What’s happening?
- Lesion of contralateral subthalamic nucleus (STN) (often lacunar stroke)
- STN normally excites GPi; losing STN → ↓ GPi activity → less inhibition of thalamus
- Net: thalamus overactive → hyperkinesia
Presentation
- Sudden onset violent, flinging movements of one side (proximal limb muscles)
Treatment
- Often improves over time
- Dopamine antagonists (e.g., haloperidol) can be used if severe
HY localization:
Ballismus = STN.
Dystonia & Dyskinesia (Often Drug-Related on Exams)
Acute dystonia (hours–days after D2 blockade)
- Sustained muscle contraction (torticollis, oculogyric crisis)
- Treat with benztropine or diphenhydramine
Tardive dyskinesia (months–years)
- Lip smacking, tongue movements, choreoathetoid movements
- Treat with VMAT2 inhibitors (valbenazine, deutetrabenazine) or switch antipsychotic
Mechanism tie-in:
D2 blockade reduces dopamine effect → shifts toward indirect pathway dominance → parkinsonism/dystonia.
Wilson Disease (Basal Ganglia + Liver)
What’s happening?
- Copper accumulation (ATP7B mutation) → basal ganglia dysfunction
Presentation
- Hepatic disease + neuro/psych symptoms
- Tremor, dystonia, parkinsonism
- Kayser-Fleischer rings
Diagnosis/Treatment
- ↓ ceruloplasmin, ↑ urine copper
- Chelation (penicillamine, trientine), zinc
High-Yield “If They Lesion X, What Happens?” Cheat Sheet
| Lesion | Net basal ganglia effect | Movement result | Classic syndrome |
|---|---|---|---|
| SNc degeneration | ↓ D1, ↓ D2 inhibition → indirect dominates | Hypokinesia | Parkinson disease |
| Striatum indirect neurons degenerate | ↓ indirect brake | Hyperkinesia (chorea) | Huntington disease |
| STN lesion | ↓ GPi excitation → ↓ thalamic inhibition | Hyperkinesia (ballismus) | Hemiballismus |
| D2 blockade (antipsychotics) | indirect becomes stronger | Parkinsonism/dystonia | EPS |
How It Shows Up on USMLE: Pattern Recognition Prompts
Classic question stems
- “Elderly man with resting tremor and rigidity…” → SNc dopamine loss → indirect pathway overactivity
- “Young adult with family history of chorea, depression…” → Huntington → indirect pathway loss
- “Sudden flinging movements after stroke…” → contralateral STN
- “Psych patient started on haloperidol develops torticollis…” → acute dystonia (treat benztropine)
One-liner rules that score points
- GPi is the brake on the thalamus.
- Direct removes the brake; indirect presses the brake.
- Dopamine is pro-movement: D1 up, D2 down (indirect down).
Mini Self-Test (Fast and High-Yield)
- Lesion of the left STN causes what?
- Right-sided hemiballismus (hyperkinesia)
- Loss of dopaminergic input to striatum does what to GPi output?
- Increases GPi inhibition of thalamus (net hypokinesia)
- Which neurotransmitter does STN use to influence GPi?
- Glutamate (excitatory)
Final Takeaway
If you remember that GPi tonically inhibits the thalamus, everything else becomes “just disinhibition math.” Direct pathway frees the thalamus to move; indirect pathway tightens the brake to stop movement; dopamine from SNc pushes the system toward movement by helping direct (D1) and suppressing indirect (D2). From there, Parkinson, Huntington, and hemiballismus become straightforward predictions—not memorized trivia.